{"commentary":{"count":136,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":69,"podcast":51,"x_thread":16},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04214288\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SERENA-2","nct_id":"NCT04214288","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=serena-2-nct04214288. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SERENA-2","arms":[{"description":"The patients will receive AZD9833 (Dose A).","label":"AZD9833 Dose A","type":"EXPERIMENTAL"},{"description":"The patients will receive AZD9833 (Dose B).","label":"AZD9833 Dose B","type":"EXPERIMENTAL"},{"description":"The patients will receive AZD9833 (Dose C).","label":"AZD9833 Dose C","type":"EXPERIMENTAL"},{"description":"The patients will receive Fulvestrant (500 mg).","label":"Fulvestrant 500 mg","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-06-16","type":"ESTIMATED"},"conditions":["Advanced ER-Positive HER2-Negative Breast Cancer"],"enrollment":{"count":240,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"AZD9833","type":"DRUG"},{"name":"Fulvestrant","type":"DRUG"}],"last_update":"2026-08-26","lead_sponsor":"AstraZeneca","official_title":"SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-08-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months)"}],"references":[{"citation":"Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, Hotko Y, Melkadze T, Nemsadze G, Neven P, Vladimirov V, Zamagni C, Denys H, Forget F, Horvath Z, Nesterova A, Ajimi M, Kirova B, Klinowska T, Lindemann JPO, Lissa D, Mathewson A, Morrow CJ, Traugottova Z, van Zyl R, Arkania E. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024 Nov;25(11):1424-1439. doi: 10.1016/S1470-2045(24)00387-5.","pmid":"39481395","type":"DERIVED"},{"citation":"Hamilton E, Oliveira M, Turner N, Garcia-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8.","pmid":"38729567","type":"DERIVED"}],"start_date":{"date":"2020-04-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04214288"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/serena-2-nct04214288"}